Wells Fargo helped pull the market lower after falling 4.6 per cent. The San Francisco-based bank reported weaker profit and revenue for the latest quarter than expected, with analysts citing lower trading fees and other miscellaneous items.Bank of America fell 3.8 per cent despite reporting a stronger profit than analysts expected, with some consternation about the size of its upcoming expenses. Citigroup, which is in the midst of a turnaround under Chair and CEO Jane Fraser, fell 3.3 per cent following i ...

PresentationGood morning. Welcome to the JPMorgan Healthcare Conference. I'm Seiji Wakao, Japan Pharma Analyst at JPMorgan. And it's my pleasure to introduce Takino-san, CEO of Ono Pharmaceutical, and welcome him to the conference. Takino-san, please go ahead.Toichi TakinoPresident, COO & Representative Director Thank you, Wakao-san, and hello, everyone. Let me start a brief introduction. I'm Toichi Takino, President and COO of Ono Pharma from Osaka, Japan and very much honored to be here to make a presenta ...

Company Overview - Ono Pharmaceutical has a long history dating back to 1717, marking its 309th year in 2023 [3] - The company has developed numerous innovative medicines, including over 10 prostaglandin-related products and the world's first PD-1 antibody, OPDIVO, launched nearly 10 years ago [3] Growth Strategy - Ono is expanding its market focus from traditional Japan and Asia to global markets [4] - In 2024, Ono acquired U.S. biotech Deciphera, aiming to enhance its specialty products and sales channels in the U.S. and European markets [4] Future Outlook - The company is positioned as an attractive investment opportunity with high potential for future growth, driven by its development pipelines [2]

獨家保薦人、[編纂] 「編纂」項下 | 編纂 |數目 : 「編纂]股股份(視乎 | 編纂]行 使與否而定) [編纂]數目 .. 「編纂]股股份(可予[編纂]) : 「編纂]數目 「編纂]股股份(可予[編纂]及視乎|編纂] 行使與否而定) 【繼臺】 : 每 股 股 份 [ 編 纂 ] 港 元,另 加 1.0% 經 紀 佣金、0.0027% 證 監 會 交 易 徵 費、 0.00565% 聯 交 所 交 易 費 及 0.00015% 會財局交易徵費(須於申請時以港 元繳足,多繳款項可予退還) : 每 股 股 份 0.00001 美 元 面 值 .. [繼營] | 繼臺] 1月14日，Exegenesis Bio Inc.向港交所主板递交上市申请，建银国际为其独家保荐人。据招股书，Exegenesis Bio Inc.凭借其自 主研发的AAVarta及SODA技术平台，开发出多元化且可扩展的产品管线，包括核心候选产品EXG001-307(SMA1型)及两款关键 候选产品，即EXG102-031和EXG202。 Exegenesis Bio Inc. (於開曼群島註冊成立之有限公司) [編纂] ...

OPKO Health Conference Call Summary Company Overview - **Company**: OPKO Health - **Key Participants**: - Elias Zerhouni - President - Adam Logal - CFO - **Industry**: Biotechnology and Clinical Diagnostics Core Business Components - OPKO Health operates a diverse range of businesses, including: - Clinical diagnostics through BioReference Health - Biotech operations via ModeX Therapeutics, focusing on therapeutics and divesting from clinical diagnostics to improve profitability [6][15] Financial Performance and Strategy - OPKO has divested approximately 40% of its clinical diagnostic business to enhance profitability, focusing on operations in New York and New Jersey [6][15] - The company is nearing break-even and profitability with its remaining clinical diagnostic business, particularly with the 4Kscore cancer diagnostic test, which has shown over 15% growth in testing [7][17] - Guidance for 2026 indicates a projected revenue growth of 3%-5% from a base of approximately $300 million, with a focus on operating efficiency rather than deep investment in commercial operations [18] Key Products and Developments - **4Kscore Test**: - Aids in identifying patients at high risk for aggressive prostate cancer, with a market potential of $25-$30 million [20][21] - Recently received FDA clearance to remove the requirement for a digital rectal exam, potentially increasing adoption [21] - **ModeX Therapeutics**: - Licensed an Epstein-Barr Virus (EBV) vaccine to Merck for $50 million upfront and potential milestones of $870 million [9][10] - The vaccine is in phase one trials, with significant potential for treating cancer and multiple sclerosis [10][25] - **Pipeline Products**: - MDX-2001: A cancer solid tumor product nearing phase 1B trials, targeting multiple cancer types [11][32] - MDX-2004: A trispecific antibody aimed at rejuvenating the immune system, currently in clinical trials [12][42] - Collaboration with Regeneron to develop multiple programs in obesity, metabolism, and cancer [13][52] Milestones and Future Outlook - The company anticipates significant milestones tied to the progression of its vaccine and therapeutic candidates, with potential financial milestones upon entering phase two trials [27][31] - The partnership with Regeneron is expected to yield candidates by the end of the year or early next year, with a focus on combination therapies [53][54] Risk Management and Clinical Trials - OPKO is managing risks associated with clinical trials, particularly concerning cytokine release syndrome (CRS) through established protocols and dose management strategies [36][39] - The company is focused on ensuring safety and efficacy in its trials, with ongoing assessments to determine the most responsive cancer types for its therapies [32][35] Conclusion - OPKO Health is strategically repositioning itself towards a more therapeutics-focused model while maintaining a profitable clinical diagnostics segment. The company is poised for growth with a rich pipeline of products and strategic partnerships that could lead to significant advancements in the biotech space over the next few years [15][30]

Oculis (NasdaqGM:OCS) FY Conference January 14, 2026 04:30 PM ET Company ParticipantsRiad Sherif - CEOConference Call ParticipantsTessa Romero - Senior Biotech AnalystTessa RomeroWelcome, welcome everyone to the 44th Annual J.P. Morgan Healthcare Conference. My name is Tessa Romero, and I'm one of the senior biotech analysts here at J.P. Morgan. Our next presenting company is Oculis, and presenting on behalf of the company, we have CEO Riad Sherif. Riad, over to you.Riad SherifThank you. Thank you, Tessa. V ...

PresentationGreat. Good morning, everyone. My name is Jess Fye. I'm a biotech analyst at JPMorgan, and we're continuing our 44th Annual Healthcare Conference this morning with Mirum. First, you're going to hear a presentation from the company and then we're going to go into a Q&A session. So for all of you in the room, if you do have a question, just raise your hand so someone can bring you a microphone for the webcast. And if you're listening online, you can submit questions to the portal, and I can read t ...

Company Overview - Annexon is a biotech company based in Bayera, focusing on immunotherapy to treat neuroinflammatory diseases, with a mission to deliver transformative therapies for patients [2] - The company has two major registrational stage programs that target a market opportunity exceeding $10 billion and aim to treat over 10 million patients annually [2] Product Pipeline - The lead program is focused on dry Age-related Macular Degeneration (AMD) with geographic atrophy, which is a significant cause of blindness, and the drug candidate, vonaprument (ANX007), has shown substantial vision protection in affected patients [3] - The second drug candidate, tanruprubart, is aimed at treating Guillain-Barre syndrome [3]

Company Overview - NovoCure has developed, pioneered, and commercialized an effective wearable cancer therapy that is currently a standard of care [4] Leadership and Strategy - Frank Leonard, the new CEO with over 15 years at the company, emphasizes a focus on driving growth through a reorganization of the commercial organization [2][3] - The company is looking ahead to a catalyst-rich year in 2026, indicating multiple upcoming developments that could impact its growth trajectory [2][3]

PresentationWelcome, everyone, to the 44th Annual JPMorgan Healthcare Conference. My name is Tess Romero, and I'm one of the senior biotech analysts here at JPMorgan. Our next presenting company is Sana. And presenting on behalf of the company, we have President and CEO, Steve Harr.Steven HarrPresident, CEO & Director Thank you, Tessa, and thank you, JPMorgan, for having us here, and I appreciate everybody joining us here in the room and online. I think you probably know, we'll make some forward-looking sta ...